Objective: This study assessed osteoporosis knowledge deficits among cancer patients and their spouses/partners.

Design: Single-institution survey (modified version of the Osteoporosis Knowledge Assessment Tool).

Setting: The Mayo Clinic in Rochester, Minnesota.

Participants: Consecutive chemotherapy-treated cancer patients (n = 285) with their spouses/partners (n = 101).

Outcome Measures: The main outcome was the percentage of cancer patients who incorrectly conveyed that 1) cancer treatment strengthens bones (or did not know) and/or 2) male cancer patients are not at risk for osteoporosis (or did not know).

Analyses: Test scores and 95% confidence intervals (CI) as well as the correlation between patient and spouse/partner scores, are reported.

Results: 39% of patients (95% CI, 32% - 48%) thought cancer treatment strengthened bones or did not know, and 39% (95% CI, 32% - 48%) either answered that osteoporosis almost never occurred in men or did not know. The mean correct score on the modified Osteoporosis Knowledge Assessment Tool was 6.7 (95% CI, 6.7, 7.9), and scores from patients correlated with companion scores (r = 0.42; P < .001).

Conclusions And Implications: Chemotherapy-treated cancer patients and their companions have knowledge deficits concerning osteoporosis. Educational initiatives to increase awareness may be of value.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneb.2007.08.009DOI Listing

Publication Analysis

Top Keywords

cancer patients
24
chemotherapy-treated cancer
12
osteoporosis knowledge
12
cancer
9
patients
8
patients companions
8
knowledge deficits
8
knowledge assessment
8
cancer treatment
8
95% 32%
8

Similar Publications

KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.

View Article and Find Full Text PDF

Background: To develop and validate a clinical-radiomics model for preoperative prediction of lymphovascular invasion (LVI) in rectal cancer.

Methods: This retrospective study included data from 239 patients with pathologically confirmed rectal adenocarcinoma from two centers, all of whom underwent MRI examinations. Cases from the first center (n = 189) were randomly divided into a training set and an internal validation set at a 7:3 ratio, while cases from the second center (n = 50) constituted the external validation set.

View Article and Find Full Text PDF

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how changes in the Ki67 biomarker before and after neoadjuvant chemotherapy (NACT) affect survival in patients with triple-negative breast cancer (TNBC).
  • Among 1,777 TNBC patients analyzed, most showed a decrease in tumor size and Ki67 levels after NACT, though many had no change or experienced treatment discontinuation.
  • Patients with unchanged Ki67 had significantly worse overall and disease-specific survival compared to those with decreased Ki67, emphasizing the need for personalized treatment strategies based on ongoing monitoring of this biomarker.
View Article and Find Full Text PDF

Sex Differences in Melanoma Survival-a GEM study.

JNCI Cancer Spectr

January 2025

University of New Mexico Comprehensive Cancer Center, Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM, USA.

Sex differences in melanoma are prominent, with females having a significant survival advantage. However, it is unclear why we see this survival advantage. Here we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1,753 single primary melanomas from patients in the GEM study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!